Penumbra

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Penumbra and other ETFs, options, and stocks.

About PEN

Penumbra, Inc. is a thrombectomy company, which designs, develops, manufactures, and markets innovative medical products. It offers neurovascular thrombectomy and embolization and access technologies, neurosurgical tools, Penumbra LANTERN Delivery Microcatheter, and Penumbra Occlusion Device system. 

CEO
Adam Elsesser
CEOAdam Elsesser
Employees
4,500
Employees4,500
Headquarters
Alameda, California
HeadquartersAlameda, California
Founded
2004
Founded2004
Employees
4,500
Employees4,500

PEN Key Statistics

Market cap
14.09B
Market cap14.09B
Price-Earnings ratio
85.85
Price-Earnings ratio85.85
Dividend yield
Dividend yield
Average volume
2.55M
Average volume2.55M
High today
$360.49
High today$360.49
Low today
$358.21
Low today$358.21
Open price
$359.40
Open price$359.40
Volume
1.04M
Volume1.04M
52 Week high
$362.41
52 Week high$362.41
52 Week low
$221.26
52 Week low$221.26

Stock Snapshot

With a market cap of 14.09B, Penumbra(PEN) trades at $359.26. The stock has a price-to-earnings ratio of 85.85.

On 2026-01-25, Penumbra(PEN) stock moved within a range of $358.21 to $360.49. With shares now at $359.26, the stock is trading +0.3% above its intraday low and -0.3% below the session's peak.

Trading activity shows a volume of 1.04M, compared to an average daily volume of 2.55M.

The stock's 52-week range extends from a low of $221.26 to a high of $362.41.

The stock's 52-week range extends from a low of $221.26 to a high of $362.41.

PEN News

Simply Wall St 20h
Assessing Penumbra Valuation After Strong Recent Share Price Momentum

Advertisement Why Penumbra Is On Investors’ Radar Right Now Penumbra (PEN) has recently caught attention after a period of strong share price moves, with the...

Assessing Penumbra Valuation After Strong Recent Share Price Momentum
Barron's 2d
Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock.

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. Fo...

Our Boston Scientific Pick Has Stumbled. Acquiring Penumbra Will Help the Stock.
Simply Wall St 2d
Boston Scientific Penumbra Deal Recasts Growth Prospects In Thrombectomy And Neurovascular

Boston Scientific has agreed to acquire Penumbra (NYSE:PEN) in a cash and stock transaction valued at about $14.8 billion. Penumbra is expected to become a who...

Boston Scientific Penumbra Deal Recasts Growth Prospects In Thrombectomy And Neurovascular

Analyst ratings

75%

of 20 ratings
Buy
20%
Hold
75%
Sell
5%

More PEN News

TipRanks 6d
Penumbra downgraded to Hold from Buy at Canaccord

Canaccord downgraded Penumbra (PEN) to Hold from Buy with a price target of $374, up from $359. The firm cites Boston Scientific’s (BSX) agreement to acquire Pe...

TipRanks 6d
Penumbra: Rating Cut to Hold as Boston Scientific Takeout Caps Upside at $374 Deal Price

Penumbra, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst William Plovanic from Canaccord Genuity downgraded the rating...

People also own

Based on the portfolios of people who own PEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.